MatthewGSuleckiMD

PubMed

• 13 citations
  Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung can...
  Athanassios Argiris, Ju-Whei Lee, James P. Stevenson, M. Sulecki, V. Hugec, Nicholas Choong, Joel N. Saltzman, W. Song, R. M. Hansen, Tracey L. Evans, Suresh S. Ramali...> ;Annals of Oncology. 2017 Dec 1
• 6 citations
  Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF.
  M. Sulecki, Craig S. Rosenfeld, Donna Przepiorka, Elana J. Bloom, William Buhles, Richard K. Shadduck> ;The American Journal of Medicine. 1991 Mar 1
• 1 citations
  Use of granulocyte-macrophage colony-stimulating factor in patients with malignancy and bone marrow failure.
  Richard K. Shadduck, Craig S. Rosenfeld, M. Sulecki, Nabil Phillips, Donna Przepiorka, Martin Earle, Ronald G. Stoller, Samuel A. Jacobs> ;International Journal of Cell Cloning. 1990 Jan 1
• 27 citations
  Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tu...
  Hussein Tawbi, Liza C. Villaruz, Ahmad A. Tarhini, Stergios J. Moschos, M. Sulecki, F. Viverette, Janice Shipe-Spotloe, R. Radkowski, John M. Kirkwood> ;British Journal of Cancer. 2011 Sep 6
• 14 citations
  Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer
  Suresh S. Ramalingam, Judy Foster, William Gooding, Terry Evans, M. Sulecki, Chandra P. Belani> ;Cancer. 2010 Mar 1
• Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refra...
  Ramalingam, S., Forster, J., Naret, C., Evans, T., Sulecki, M., Lu, H., Teegarden, P., Weber, M. R., Belani, C. P.> ;J Thorac Oncol. 2008 Mar
• Join now to see all